Clinic Observational Detox Outcomes After Ibogaine — Davis et al. 2018 Mixed-Method (Sisko Substitute)

Definition box

Definition: Verification (2026-09-06): No peer-reviewed “Sisko” ibogaine detox outcomes paper was located in the 2016–2026 PubMed/web window. Closest strong substitute chosen: Davis A.K., Renn E., Windham-Herman A.-M., Polanco M., & Barsuglia J.P. (2018) *A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification*, *Journal of Psychoactive Drugs* 50(4):287–297 (doi: 10.1080/02791072.2018.1487607; PMID 30020025). Secondary mixed-methods analysis from the same Mexico clinic retrospective program as Davis/Barsuglia 2017: n=73 chronic opioid users compared as treatment responders vs non-responders, plus qualitative coding of open-ended persisting-effect themes (gratitude, meaning, sacredness, relational change, ongoing challenges). Route = clinic oral ibogaine detoxification context—not psychoactive IV ibogaine infusion. Observational; not RCT; not a cure claim; not FDA-approved. Ibogaine is U.S. Schedule I. QTc/cardiac risk remains central.

Quotable answer (55 words)

No peer-reviewed Sisko ibogaine detox paper was found for 2016–2026. Davis and colleagues’ 2018 Journal of Psychoactive Drugs mixed-method study (n=73) maps persisting psychosocial effects after clinic oral ibogaine detoxification. Themes are not controlled efficacy proof and not psychoactive IV ibogaine infusion evidence. Screen for QTc risk first.

Why this spoke exists (substitution rule)

The inventory asked for “Sisko or related clinic observational detox outcomes.” After DOI/PubMed verification, clinic-adjacent peer-reviewed detox literature in-window is better represented by the Davis/Barsuglia Mexico program secondary analysis than by non-peer-reviewed marketing case studies. Soft CTA: /safety-and-screening → /apply.

Alternates considered: Schenberg Brazil series (used for stimulant spoke 110); Malcolm 2018 COWS (already draft 102); Mash 2018 N=191 (already draft 74).

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Davis A.K., Renn E., Windham-Herman A.-M., Polanco M., Barsuglia J.P. *J Psychoactive Drugs*. 2018;50(4):287–297. doi 10.1080/02791072.2018.1487607. PMID 30020025 | | Type | Mixed-method secondary analysis (quantitative responder contrast + qualitative theme coding) | | Parent cohort | Same Mexico clinic retrospective survey family as Davis et al. 2017 | | Analytic N | 73 (of 88 in the 2017 outcomes paper; 15 missing persisting-effects measures) | | Route | Oral clinic ibogaine detoxification—not psychoactive IV brand study | | Focus | Persisting psychosocial effects linked to positive outcomes; challenges after detox | | What it is not | RCT; urine-verified 12-month primary; Sisko-authored paper; FDA approval; IV proof; cardiac QT trial |

Methods (plain language)

Authors split participants into responders vs non-responders using opioid-use outcome definitions from the parent survey, then compared questionnaire scores and coded free-text answers about what felt lasting after detox. Qualitative themes help explain *how* people narrate benefit—they do not upgrade the design into a randomized trial.

Key findings (no hype)

• Responders more often described lasting gratitude, meaning, and sacred/spiritual framing of the detox experience.
• Open-ended answers also documented ongoing challenges (craving re-emergence, life stressors, incomplete psychosocial supports)—important anti-hype content.
• Mixed methods enrich the 2017 percentage headlines without proving causality.
• Authors situate results as hypothesis-generating for integration and aftercare research.

Honest reading: Clinic oral detox is experienced by many as psychologically “sticky”; stickiness ≠ lifelong cure and ≠ IV brand proof.

How it sits beside related detox observationals

| Paper | Distinct contribution | |-------|----------------------| | Davis/Barsuglia 2017 | n=88 subjective opioid use outcomes (/blog/davis-barsuglia-2017-ibogaine-survey) | | Davis 2018 mixed-method | Persisting psychosocial themes + responder contrast (n=73) | | Malcolm 2018 | Timed COWS/SOWS/BSCS n=50 (/blog/ibogaine-oud-case-series-2016-2020) | | Brown & Alper 2018 | SOWS + ASI to 12 months (/blog/brown-alper-2018-ibogaine-oud) | | Mash 2018 | Large open-label craving/mood N=191 (/blog/mash-2018-ibogaine-detox-frontiers) |

Cardiac / YMYL gap

Persisting-effects psychology papers rarely carry QTc tables. Readers still need /blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-cardiovascular-complications-review, /blog/corkery-ibogaine-fatalities, and /safety-and-screening. Mexico clinic observation ≠ U.S. FDA clinic.

Route honesty & entity clarity

Oral clinic detox narratives ≠ physician-supervised psychoactive IV ibogaine infusion. Supportive IV fluids/magnesium ≠ psychoactive IV ibogaine (/blog/ibogaine-oral-vs-iv; /blog/electrolytes-support-iv-vs-psychoactive-iv).

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Secondary analysis | Depends on parent survey biases | | Self-selected responders | May over-represent positive narrators | | No randomization | Setting and aftercare confound | | Qualitative coding | Themes are interpretive, not effect sizes | | Cardiac not primary | Incomplete risk picture alone |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Sisko proved clinic detox cures OUD” | False (no verified Sisko peer-reviewed paper; this substitute is not a cure claim) | | “Proves psychoactive IV ibogaine” | False | | Useful labeled oral detox psychosocial signal? | Yes—with method class stated |

What “persisting effects” means in plain language

Clinic patients often describe ibogaine detox as more than a quiet medication day: autobiographical material, spiritual framing, interpersonal resolve, and a sense that something “stuck.” Davis 2018’s mixed-method design tries to catalog those narratives systematically—comparing people who met responder definitions on opioid outcomes with those who did not, then coding open text for recurring themes.

That is valuable for integration and aftercare design (/blog/ibogaine-aftercare-integration). It is not a license to market “permanent personality upgrades” or to imply that psychosocial stickiness removes cardiac risk.

Aftercare reminder tied to this paper

If gratitude and meaning rise while housing, trauma care, and contingency management are absent, relapse risk remains. Pair this spoke with longer observational durability papers (Brown/Noller) and with honest AE/fatality literacy (/blog/ona-2022-ibogaine-adverse-events-review). Mexico provisional pathways still require screening rigor comparable to any YMYL elective psychoactive exposure.

SEO misuse patterns to refuse

• “New Sisko study proves ibogaine detox.” (No verified Sisko peer-reviewed paper.)
• “73 patients cured—science confirms.” (Responder contrasts ≠ cures.)
• “IV infusion delivers the same persisting effects.” (Route not studied as psychoactive IV brand.)

Soft CTA

Meaning-making after detox is not a cardiac screen. Start: /safety-and-screening → /apply.

FAQ

Was a Sisko peer-reviewed detox paper found? No verified 2016–2026 peer-reviewed Sisko ibogaine detox outcomes paper; this spoke substitutes Davis et al. 2018.

What is the substitute DOI? **10.1080/02791072.2018.1487607** (PMID **30020025**).

Is it an RCT? No. Mixed-method observational secondary analysis.

Was the route IV ibogaine? No—clinic oral detox context.

Does gratitude prove efficacy? No. Themes describe experience; they do not replace controlled trials.

Does this erase cardiac risk? No.

Is ibogaine FDA-approved? No. Schedule I.

Where should screening start? /safety-and-screening → /apply.

Sources (selected)

1. Davis A.K. et al. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1487607. PMID: 30020025.
2. Davis A.K. et al. *J Psychedelic Stud*. 2017. doi: 10.1556/2054.01.2017.009.
3. Malcolm B.J. et al. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1447175.
4. Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
5. Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
6. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
7. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

No Sisko peer-reviewed paper verified; Davis 2018 mixed-method oral-clinic detox analysis is the substitute—not a cure claim and not psychoactive IV ibogaine efficacy proof.